Find out how ADT + ARPI outperforms ADT alone in mHSPC, boosting survival and treatment persistence. Read more on real-world ...

Four-year follow-up demonstrates preserved bowel, urinary, and sexual outcomes with consistent, reproducible spacing BETHLEHEM, Pa., Nov. 7, 2025 ...

Prostate cancer is something that nobody wants to have. Thankfully, with modern medical advancements, there are different ...

A European study has demonstrated a sustained long-term reduction in prostate cancer mortality through prostate-specific ...

A European study has demonstrated a sustained long-term reduction in prostate cancer mortality through prostate-specific antigen (PSA) screening. However, the findings also highlight the issue of ...

For Jose Espinoza, peace has always been found in the quiet moments, but in 2022, a persistent pain in his back began to steal that peace away.

The Vanguard Path study is led by researchers at the University of Oxford and funded with £1.9 million from the charity Prostate Cancer UK.

Based on patterns of recurrence-free survival (RFS) over time in some studies, the researchers determined that 5-year RFS may be a suitable surrogate for measuring cure.

Last month, IceCure Medical’s tumor-freezing technology won FDA approval for treating early-stage breast cancer. Now, the Israel-based medtech is touting a new study showing its procedure combined ...

Dr. Adam Weiner answers common questions about the costs of androgen deprivation therapy (ADT) for advanced prostate cancer and how to find help paying for it.